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Abstract
Aims To determine whether blood glucose test strip
(BGTS) utilization in patients with type 2 diabetes (T2D) is
associated with the type of diabetes therapy, classified
according to hypoglycemic risk.
Methods A retrospective, longitudinal (2006–2012) study
of Canadian private drug plans (PDP) and Ontario Public
Drug Programs (OPDP) prescription claims was conducted.
Analyses were restricted to patients with T2D with or
without a claim for BGTS. Daily BGTS utilization
(TS/patient/day) was evaluated by diabetes therapy classi-
fied by hypoglycemic risk. Multivariate analyses were
conducted to identify determinants of BGTS utilization.
Results The T2D cohort comprised 5,759,591 observa-
tions from 1,949,129 claimants. Mean BGTS utilization
was 0.84 TS/patient/day and differed between PDP and
OPDP (0.66 vs. 1.00). Daily utilization was greatest in
patients receiving therapy associated with a pre-defined
high risk of hypoglycemia [insulin: basal ? bolus (2.16),
premixed (1.65), basal (1.16), other insulin regimens
(2.13), and sulfonylureas (0.74)] versus non-sulfonylurea
non-insulin-based regimens (0.52). For non-insulin ther-
apy, BGTS utilization was greater for patients on multiple
non-insulin therapies versus monotherapy (0.74 vs. 0.53
TS/patient/day). In multivariate analyses, drivers for BGTS
utilization included insulin use, previous BGTS use, and
female gender. Previous diabetes therapy and duration of
therapy were negatively correlated with BGTS utilization.
Conclusions BGTS utilization varies depending on the
type of therapy used to treat T2D according to hypo-
glycemic risk. Decision making regarding BGTS needs to
account for robust analyses of current utilization and its
value in those settings, including in patients not receiving
diabetes therapy and the prevalence of circumstances
conducive to more intensive monitoring.
Keywords Blood glucose self-monitoring  Type 2
diabetes mellitus  Utilization
Introduction
National and international clinical practice guidelines for
the management of diabetes currently recommend indi-
vidualized self-monitoring of blood glucose (SMBG) based
on several factors, such as the patient’s type of diabetes and
diabetes therapy regimen [1–7]. While patients with type 1
diabetes (T1D) require insulin, patients with type 2 dia-
betes (T2D) may manage their disease with diet, exercise,
and a variety of treatments (e.g., non-insulin-based therapy,
and insulin) [1–7]. SMBG allows for the detection of
hyperglycemia and hypoglycemia to inform disease man-
agement [2, 3]. Compared with insulin, the risk of hypo-
glycemia associated with non-insulin therapies is lower and
is generally limited to secretagogues [2, 3, 8, 9].
Given the cost of blood glucose test strips (BGTSs), the
increasing global prevalence of T2D and the availability of
new diabetes therapies with lower risk of hypoglycemia,
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there is considerable interest in ensuring the appropriate
use of SMBG in patients with T2D. However, interna-
tionally, patient-reported BGTS utilization varies markedly
[10]. Also, costs per test strip (TS) vary from $0.35
(Australia) to $3.11 (India) (adjusted to US dollar pur-
chasing power, 2006) [10]. Recently, BGTS represented
the third largest expenditure for the public drug formulary
in Ontario, Canada [10, 11]. To economize SMBG, in
2009, the Canadian Agency for Drugs and Technologies in
Health (CADTH) recommended limiting BGTS use to
insulin-dependent and gestational diabetes while with-
drawing it from most patients with T2D on non-insulin
diabetes therapy or no therapy [12]. The CADTH recom-
mendations were criticized by the Canadian Diabetes
Association (CDA) for undervaluing the merits of self-
management in non-insulin-treated patients and for not
accounting for the increased risk of hypoglycemia associ-
ated with secretagogues [13]. Notably, Gomes et al.
observed a 33 % increase in daily BGTS utilization for
non-insulin therapies associated with hypoglycemia versus
those not associated with hypoglycemia [14].
Despite this, important questions persist. There are
limited data on differences in SMBG across specific regi-
mens associated with differential hypoglycemic risk.
Additionally, the prevalence and value of SMBG in
patients with T2D not treated with a pharmacologic agent
are not well understood. Further, there is a lack of infor-
mation on the impact of alternative methods of analyzing
BGTS utilization employed to date. The objective of this
study was to build on the existing literature, to determine
whether BGTS utilization in patients with T2D is associ-
ated with the type of diabetes therapy, classified according
to hypoglycemic risk.
Methods
Two claims databases were used to identify patients with
T2D in Canada from January 1, 2006, to December 31,
2012. These two databases capture public (Ontario
Public Drug Programs [OPDP]) and private (private drug
plans [PDP]) market claims for BGTS. The OPDP cov-
ers approximately 2.5 million claimants in Ontario and
115 million prescriptions annually. The majority (68 %)
of claimants in the OPDP are aged C65 years, with
*32 % on social assistance, disability, catastrophic ill-
ness, or other benefits [15]. The OPDP database has a
100 % capture rate. The PDP covers 10 million Cana-
dians across Ontario (34 %), Quebec (28 %), Western
Canada (29 %), and Atlantic Canada (9 %), and 100
million prescriptions annually. The PDP database has a
70 % capture rate.
Study design
This study built on earlier methodology [12, 15] to eluci-
date the impact of study design and sampling on BGTS
utilization. Previous studies assessed BGTS utilization in
all patients with diabetes (T1D and T2D) who had at least
one BGTS prescription claim, which does not account for
differences in the two populations. Patients were assigned
to yearly cohorts based on the most prominent diabetes
therapy received during that period. Since patients may be
on multiple therapies over the course of a year, a more
specific sampling method may yield different results.
Utilization was assessed according to diabetes therapy
type; however, some studies classified all insulins in a
single category [14, 16] and/or did not account for hypo-
glycemic risk associated with secretagogues [14]. Yet,
unique regimens may be associated with different patterns
of SMBG. Neither study accounted for non-BGTS users in
its estimates of utilization.
Given the above, once the results of the initial CADTH
study [16] were reproduced, the following methodological
changes were implemented and the independent effect of
each explored: (1) addition of non-BGTS users; (2) limit-
ing the population to patients with T2D according to the
eligibility criteria listed below; (3) extending the study
period through 2012; (4) using a longitudinal approach, to
capture all diabetes therapies over the entire study time-
frame, rather than attributing BGTS utilization to the
dominant regimen (Fig. 1); and (5) combining points 1–4
in the overall analysis.
The longitudinal approach to measuring diabetes ther-
apy allowed BGTS utilization to be attributed to unique
regimens (i.e., multiple observations from a single claimant
were possible; Fig. 1). Diabetes therapy and BGTS uti-
lization were inferred from claims filed. Diabetes therapy
claims were chronologically ordered per patient, with
combination therapies determined by the overlapping dates
for each agent. A treatment duration of 90 days from the
therapy claim date was used as a default. Otherwise, a new
diabetes therapy claim extended the treatment duration or
signified a treatment addition. Where a delay of less than
60 days existed between the default duration expiry and a
new claim extending the therapy, an adjustment was made
to infer treatment continuity. A period of BGTS utilization
(TS/day) was allocated to therapy using three rules based
on the timing and duration of BGTS claims. If the time
between BGTS claims was less than 180 days, the duration
of a BGTS claim was determined as the time from one
claim to the next. If there was a period of at least 180 days
between claims, the duration of the initial claim was set at
90 days. Finally, if the duration of a BGTS claim spanned
two diabetes therapies, the number of BGTS claimed was
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divided between regimens proportional to the number of
BGTS claim days that overlapped with each therapy.
Eligibility criteria
Patients were included in the analysis if they filed a claim
for BGTS only (with no diabetes therapy), a non-insulin
diabetes therapy, or any basal, rapid, or premixed insulin
(human or analog). Those claiming either basal insulin only
continuously, premixed monotherapy at any point in the
analysis period, or a non-insulin diabetes therapy at any
point in the study period, were classified as T2D. Non-
insulin diabetes therapy included metformin (Met), secre-
tagogues (sulfonylureas [SU] and postprandial glucose
regulators [PPGR]), thiazolidinediones (TZD), dipeptidyl
peptidase-4 inhibitors (DPP4), prandase, and glucagon-like
peptide-1 receptor agonists (GLP-1). As determined
through historical product use, patients on insulin-only
regimens that were not classified as T2D (i.e., patients with
T1D) were excluded. Patients who were new to the data-
base in the 6 months prior to their first claim were also
excluded from the analysis.
Statistical analyses
Mean BGTS utilization was reported as per patient per day
(TS/patient/day) by type of diabetes therapy. Given the
extent of data capture, the sample means reported are
nearly exact point estimates of the population mean. Dia-
betes therapies were classified according to risk of hypo-
glycemia. Non-insulin diabetes therapies, basal insulin
only, premixed insulin only, and prandial insulin regimens
were all considered to be associated with differential BGTS
utilization due to the heterogeneous risk for hypoglycemia.
At the cohort level, per patient daily BGTS utilization was
compared across these categories of therapy.
Multivariate analyses were conducted to identify addi-
tional determinants of BGTS utilization; the variables
considered are listed in Table 1. The cohort characteristics
of ‘Public’ and ‘Private’ were too heterogeneous to com-
bine the datasets (e.g., age, socioeconomic status, and drug
coverage). Experience with previous diabetes therapy
(‘Diabetes Treatment Experience’) or BGTS (‘BGTS
Experience’) was determined by checking for previous
diabetes therapy or BGTS claims in the 6 months prior to
the first claim during the study. The ‘Experience’ of
patients who did not have a previous claim was classified
as ‘Naı¨ve’ versus ‘Experienced.’ The ‘Event (over time)’
variable was included to explore the effect of key research
findings on BGTS utilization [14, 16–20]. An approximate
cutoff date of July 2009 was used to account for the
potential effect of both the ACCORD study [17], which
found that intensive glycated hemoglobin control increased
mortality and did not lower cardiovascular risk, and studies
investigating the utilization and value of SMBG [12, 14,
16, 18–20].
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After eliminating redundant/highly correlated vari-
ables (e.g., ‘Time on any Therapy’ removed as it was
correlated with ‘Duration of Therapy’) and exclusion of
others with limited rationale (e.g., ‘Related Complica-
tions’), the following were included in the final multi-
variate analysis: diabetes product [Met, SU, PPGR, TZD,
DPP4, prandase, GLP-1 (for PDP dataset only), Basal,
Rapid, Premixed], diabetes therapy class (insulin ther-
apy, non-insulin therapy, both, none), Gender, Age
Group, Province (for PDP dataset only), Diabetes
Treatment Experience, Duration of Therapy, BGTS
Experience, and Event (over time).
The final multivariate analyses were completed on a
random sample of 0.5 % of the full cohort to evaluate
the significance of determinant effects in a clinically
meaningful sample size. To adjust for the correlation of
utilization within patients, a generalized linear mixed
model was used [21]. All statistical analyses were con-
ducted in SAS/STAT version 9.3 (Cary, NC). Adjusted
means are presented to account for different patient
dependencies.
Results
Compared with earlier studies from a similar sample [12,
14, 16], the method adopted in the current study resulted in
lower estimates of overall mean daily BGTS utilization
(Table 2). In order to estimate the effect of each revised
step to the methods, the results from the earlier study were
approximately replicated across the therapeutic categories
[16]. The original study reported a total mean BGTS uti-
lization of 1.47 TS/patient/day across 472,578 patients.
Replication of the cohort resulted in a total mean BGTS
utilization of 1.45 TS/patient/day across 481,913 patients.
The inclusion of BGTS non-users or using the longitudinal
approach each independently resulted in markedly lower
estimates of BGTS utilization (1.01 and 1.02 TS/pa-
tient/day, respectively). The effects of other steps were less
pronounced. For insulin-alone claimants, limiting the
cohort to T2D lowered average utilization from 2.94 to
2.81 TS/patient/day. Utilization estimates for other treat-
ment categories were unaffected. Extending the cohort
window from 2006 to 2012 resulted in a greater estimate of
utilization among insulin-alone claimants from 2.94 to 3.10
TS/patient/day. Total and other therapy-specific mean
estimates of BGTS utilization closely approximated the
original 2006 estimates. The cumulative effect of the
revised methods was BGTS utilization estimates that were
less than those produced from any individual, independent
revision. The total mean BGTS utilization from 2006
through 2012 measured using the revised method was 0.84
TS/patient/day.
Cohort characteristics
The T2D sample was comprised of 1,949,129 claimants,
including 63.7 % (n = 1,241,086) from the PDP cohort
(Table 3). The OPDP cohort included similar percentages
of males and females, and 44.7 % of patients had age
missing from their records. The PDP cohort consisted of a
greater percentage of males (53.0 %), and the majority of
patients were in the 40–59 (43.6 %) and 60–79 (42.3 %)
age groups. The distribution of diabetes therapy was sim-
ilar across both cohorts with the majority of patients clin-
ically managed using non-insulin diabetes therapy alone
(OPDP, 55.1 %; PDP, 53.7 %). The percentage of BGTS
users not on a diabetes therapy (27.4 %) far outnumbered
those on an insulin-only regimen (7.3 %) and remained
greater even when those using non-insulin diabetes therapy
in combination with insulin were factored in (18.4 %). A
greater percentage of patients in the OPDP cohort were on
an insulin and non-insulin diabetes therapy regimen
(OPDP, 15.4 %; PDP, 8.6 %). Across both cohorts, the
majority of patients entered the study previously using
Table 1 Cohort variables considered for multivariate analysis
Cohort variables Description
Diabetes drug Met, SU, PPGR, TZD, DPP4, prandase,
GLP-1a, basal, rapid, premixed
Diabetes class Insulin therapy, non-insulin therapy, both,
none
Gender Male, female, unknown
Age group, years \20, 20–39, 40–59, 60–79, 80?
Payer Public, private




BGTS experience Naı¨ve, experienced
Event (over time) Research findings on BGTS (i.e., ACCORD,
CADTH recommendations)
(Before July 2009, after July 2009)
Duration on line of
therapy
Continuous (no. of days)
Time on therapy Continuous (no. of days)
Time on any therapy Continuous (no. of days)
Related
complications
All, some, none (anti-infective, hypertension,
dyslipidemia, ophthalmic)
Interaction Between therapies
BGTS blood glucose test strips, CADTH Canadian Agency for Drugs
and Technologies in Health, DPP-4 dipeptidyl peptidase-4, GLP-1
glucagon-like peptide-1 agonist, Met metformin, PDP private drug
plans claims database, PPGR postprandial plasma glucose regulator,
SU sulfonylureas, TZD thiazolidinedione
a GLP-1 included in PDP only
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neither diabetes therapy (Diabetes Treatment Experience
‘Naı¨ve’: OPDP, 64.3 %; PDP 81.4 %) nor BGTS (BGTS
Experience ‘Naı¨ve’: OPDP, 75.3 %; PDP, 90.9 %).
Bivariate analysis
Each claimant may have contributed more than one
observation depending on the number of unique treatment
regimen courses used over follow-up. Whereas Table 3
reports the distribution of sample characteristics by clai-
mant, bivariate and multivariate analyses accounted for a
total of 5,759,591 observations by unique treatment regi-
men course used over follow-up.
Overall, BGTS utilization was greatest in claimants
receiving therapy associated with a pre-defined high risk of
hypoglycemia (e.g., SU, basal ? bolus insulin regimens;
Table 4). For claimants on any non-insulin therapy, BGTS
utilization was greater for those on multiple non-insulin
therapies, compared with others on one non-insulin therapy
(0.74 and 0.53 TS/patient/day, respectively). Use of SU
was associated with greater BGTS use, compared with non-
insulin-non-SU therapies (0.74 and 0.52 TS/patient/day,
respectively). For claimants on any insulin therapy, BGTS
utilization was greater for those on insulin-only therapy,
compared with others on both insulin and non-insulin
therapies (1.81 and 1.59 TS/patient/day, respectively).
BGTS utilization was greatest for claimants on
basal ? bolus regimens, followed by those on premixed
insulins and others on basal-only regimens.
Generally, the differences observed were consistent for
both databases. Utilization of BGTS tended to be greater in
the OPDP database, compared with the PDP database
(overall: 1.00 TS/patient/day and 0.66 TS/patient/day,
respectively), irrespective of therapy type. For claimants
not on any diabetes therapy, BGTS utilization averaged
0.78 (OPDP, 0.82; PDP, 0.75) TS/patient/day.
Multivariable analysis
Across a random 0.5 % sampling of each cohort, multi-
variable-adjusted differences between the diabetes therapy
classifications (insulin alone, insulin ? non-insulin (both),
non-insulin, and none) were statistically significant
(P\ 0.0001 for both cohorts). The significance of
Table 2 Mean daily BGTS utilization applying different methodological considerations





































































































BGTS blood glucose test strips; CADTH Canadian Agency for Drugs and Technologies in Health, OPDP Ontario Public Drug Programs claims
database, PDP private drug plans claims database, T2D type 2 diabetes
a Values in row one are taken from the CADTH report [18] and are provided for comparison only
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differences between insulin alone and insulin ? non-in-
sulin (both) treatment regimens was inconsistent across the
two cohorts. Differences between insulin-based regimens
(insulin alone or insulin ? non-insulin [both]) and either
non-insulin or no therapy were generally significant
(P\ 0.0005). Using this sampling method, there were
insufficient data to determine a significant statistical dif-
ference between insulin alone and no therapy in the PDP
cohort (P = 0.08). Similarly, there were insufficient data to
determine significant statistical differences between
specific non-insulin therapies in the analysis conducted.
Across the OPDP and PDP multivariable predictive
models developed, a number of variables were consistently
and significantly associated with BGTS utilization. Insulin
use (Basal, Rapid, Premixed), BGTS Experience, and
Gender (female) had independent, positive effects on
BGTS utilization. In contrast, Diabetes Treatment Experi-
ence and Duration of Therapy negatively impacted BGTS
utilization. Other variables including specific non-insulin
therapies, Age and Event (over time), had inconsistent
effects across the two cohorts.
Discussion
The utilization of BGTS in patients with T2D receiving
diabetes therapy associated with hypoglycemia exceeds that
of patients receiving other diabetes therapies. Consistent
with earlier findings [14] and guideline recommendations
[1], at the population level BGTS utilization was greater for
secretagogue-containing non-insulin regimens, compared
with other non-insulin regimens. The utilization of BGTS
was greater for more complex insulin-based regimens
requiring multiple daily injections, with basal ? bolus
regimens achieving the highest utilization. Additionally, the
study demonstrated substantial SMBG among patients not
on a diabetes therapy. As previously noted [12, 14, 16, 22],
the frequency of use generally increased with the intensity
of the treatment regimen, from non-insulin to insulin regi-
mens. In multivariate analyses, drivers for BGTS utilization
in both public and private claims databases included insulin
use, previous BGTS use, and female gender. Previous dia-
betes therapy and duration of therapy were negatively cor-
related with BGTS utilization.
Table 3 Patient cohort
characteristics at study inclusion
Characteristic, % Unique claimants










































































BGTS blood glucose test strips, OPDP Ontario Public Drug Programs claims database, PDP private drug
plans claims database
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For therapies associated with hypoglycemia, the risk of
a hypoglycemic event exists with the administration of
each dose. Perhaps for this reason, Canadian guidelines
recommend SMBG at least as frequently as insulin is
administered [1]. Bolus insulin therapy is administered
several times a day with each meal, premixed insulin is
administered twice daily, and basal insulin regimens are
typically administered once or twice daily [23]. The current
study showed that patients with T2D managed with basal–
bolus insulin regimens use up to a mean of 2.16 TS/pa-
tient/day, followed by premixed insulin (1.65 TS/pa-
tient/day), and basal insulin (1.16 TS/patient/day). The
difference relative to guidelines was most pronounced
among patients on private health plans. The findings indi-
cate that BGTS utilization for bolus and premixed regi-
mens is lower than recommended in these patients.
The utilization of BGTS in patients on a basal insulin
regimen exceeding the minimum recommendation may be
explained by the utilization of specific products and their
properties. Over the timeframe of this study, the proportion
of basal insulin prescriptions for neutral protamine Hage-
dorn (NPH) insulin was substantial, ranging from 71 % in
2007 to 40 % in 2012 [24]. Twice-daily injection of NPH
insulin is commonly required to provide 24-hour basal
coverage due to its pharmacokinetic properties [25]. Taken
together with the guideline recommendations, the dosing
frequency of NPH insulin may contribute to BGTS uti-
lization among patients treated with basal insulin alone
exceeding the default minimum of one TS/patient/day.
Further, NPH insulin is associated with an increased risk of
hypoglycemia relative to other basal insulin regimens [26,
27], independent of its greater dosing frequency [28]. The
prevalent use of NPH insulin in the study setting may have
contributed to the mean BGTS utilization observed.
Conversely, the Canadian guidelines do not specify a
frequency of testing for patients with T2D managed with-
out insulin, but instead suggest that the testing should be
individualized [1]. In the current study, those managed
without insulin used 0.61 TS/patient/day. The data from
this study may reflect the individualized nature of BGTS
Table 4 BGTS utilization across therapy classes for T2D among claims beneficiaries in the OPDP and PDPa







No therapyb 0.82 [21.3] 0.75 [26.5] 0.78 [24.3]
Non-insulin-based
regimensc
Non-SU Monotherapy 0.67 [24.0] 0.36 [28.6] 0.51 [26.6]
?non-SU, non-
insulin
0.84 [3.5] 0.45 [5.6] 0.58 [4.7]
Total 0.68 [27.5] 0.37 [34.2] 0.52 [31.3]
SU Monotherapy 0.74 [7.3] 0.35 [4.7] 0.61 [5.8]
?non-insulin 0.96 [18.3] 0.51 [13.0] 0.78 [15.3]
Total 0.90 [25.6] 0.48 [17.7] 0.74 [21.1]
Insulin-based regimens Basal insulin Monotherapy 1.52 [3.3] 0.84 [5.0] 1.11 [4.3]
?non-insulin 1.50 [5.1] 0.89 [4.3] 1.21 [4.6]
Total 1.51 [8.4] 0.87 [9.3] 1.16 [8.9]
Basal ? bolus
insulin
Monotherapy 2.68 [3.3] 1.98 [4.6] 2.24 [4.1]
?non-insulin 2.44 [2.3] 1.64 [2.4] 1.99 [2.4]
Total 2.60 [5.6] 1.87 [7.0] 2.16 [6.4]
Premixed insulin Monotherapy 1.83 [3.6] 0.94 [1.3] 1.64 [2.3]
?non-insulin 1.86 [3.0] 1.10 [1.0] 1.68 [1.9]
Total 1.84 [6.7] 1.01 [2.3] 1.65 [4.2]
Other insulind Monotherapy 2.44 [2.8] 2.00 [2.0] 2.24 [2.4]
?non-insulin 2.14 [2.1] 1.50 [1.0] 1.91 [1.5]
Total 2.33 [4.9] 1.86 [3.0] 2.13 [3.8]
BGTS blood glucose test strips, OPDP Ontario Public Drug Programs claims database, PDP private drug plans claims database, SU sulfony-
lureas, TS test strips, T2D type 2 diabetes
a Observations represent unique treatment regimens (i.e., multiple observations per claimant are possible)
b Excludes patients with prediabetes or T2D not using BGTS
c ‘Non-insulin’ includes oral anti-diabetic therapies and glucagon-like peptide-1 receptor agonists
d ‘Other insulin’ includes combinations of insulin-based regimens
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utilization according to the type of non-insulin therapy,
with patients on SU using more BGTS.
The utility of SMBG in T2D treated with non-insulin
antidiabetic therapy is tenuous [1]. Despite the debate,
systematic reviews of the literature demonstrate a finite
benefit for glycemic control associated with SMBG [29–
32]. Health technology assessments from different regions
report conflicting conclusions regarding the cost-effec-
tiveness of SMBG for patients with T2D treated with non-
insulin therapies using conventional willingness-to-pay
thresholds [33–36]. The implications of SMBG on gly-
cemic control and hypoglycemic events are controversial
or not well studied [16, 29, 37].
Differences in BGTS utilization among T2D were
investigated employing alternative methods relative to
existing studies. The methodology used in this study builds
on approaches used previously to assess BGTS utilization
[14, 16]. Compared with earlier studies, unique patient
treatment regimens were analyzed to estimate utilization
from nearly 6 million observations. In this study, BGTS
utilization over 7 years was investigated. Patients with
diabetes who did not use BGTS were also analyzed, as
were patients utilizing BGTS without concomitant use of
diabetes therapy, to allow for a more accurate estimation of
average BGTS utilization across the diabetes population.
When non-BGTS users were included, estimates of the
average utilization were lower than those predicted by
Gomes et al. (1.22 TS/patient/day) and CADTH (1.38–1.56
TS/patient/day) [14, 16]. Including these patients accoun-
ted for the increasing proportion of patients on insulin who
included SMBG as part of their diabetes management. Not
accounting for this biases utilization estimates among non-
insulin therapy users to greater values. The current analysis
accounted for more specific use of SMBG in the clinical
management of T2D, which may be important when con-
sidering the policy implications. Additionally, the popula-
tion was limited to patients with T2D. This approach
allowed several novel explorations of determinants of
BGTS utilization such as BGTS Experience, Diabetes
Treatment Experience, and Duration of Therapy.
Further research is required to understand the effect of
other variables on BGTS utilization. Previous experience
with BGTS generally increased utilization, which may be
due to familiarity and patient satisfaction with SMBG.
Alternatively, greater utilization among patients previously
using BGTS may represent bias toward those adherent to
SMBG. The observation that BGTS utilization decreased
with duration of therapy was consistent with the general
finding of poor SMBG adherence [38]. Experience with
self-management of the disease may also contribute to a
decreased dependence on SMBG. The effect of these
changes to SMBG on patient outcomes is largely unknown.
A few limitations of the study were considered. First,
BGTS utilization and diabetes therapy data were limited to
claims for these benefits. As such, they may neither
account for wastage nor reflect exact usage [39]. Second,
BGTS utilization for patients funding treatment themselves
could not be included in the analyses. Likewise, unfiled
PDP claims were not captured. Third, both databases
contain distinct population samples with the potential for
duplicate patients in both datasets. From a payer perspec-
tive, the claims analysis approach accounted for the
healthcare resource utilization associated with BGTS.
Further work is required to understand BGTS utilization
from a societal perspective. Finally, in the current study,
private and public plans were not directly compared. Dif-
ferences in the demographics and level of coverage
between the two insurance plans could affect utilization.
For instance, the private database contained younger
working-age patients who typically have higher co-pay-
ments than patients on public drug plans and therefore may
be less likely to refill prescriptions. A recent study evalu-
ating BGTS utilization has indicated that patients use more
TS if they are more easily accessible [40]. In this multi-
variate analysis, drivers for BGTS utilization were similar
for the public and private cohorts; however, magnitudes of
utilization differed.
Overall, the results of this study show that BGTS uti-
lization varies depending on the type of therapy used to
treat T2D. Decision making regarding BGTS needs to take
into account robust analyses of current utilization, includ-
ing the roles of SMBG in prediabetes or patients on no
diabetes therapy, as well as an understanding of the
prevalence of individually unique circumstances conducive
to more intensive monitoring. Only then can BGTS use,
and subsequently costs, be contained without compromis-
ing patient outcomes.
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